Balstilimab Biosimilar – Anti-PDCD1, PD1, CD279 mAb – Research Grade

Description of Balstilimab Biosimilar - Anti-PDCD1, PD1, CD279 mAb - Research Grade

Balstilimab Biosimilar: A Promising Antibody Targeting PD-1 for

Cancer Treatment

Balstilimab biosimilar, also known as anti-PDCD1, PD1, CD279 mAb, is a novel antibody designed to target and inhibit the programmed cell death-1 (PD-1) protein. PD-1 is a checkpoint protein that plays a critical role in regulating the immune response and preventing autoimmunity. However, cancer cells can hijack this mechanism to evade the immune system and continue to grow and spread. Balstilimab biosimilar works by blocking the PD-1 protein, thereby allowing the immune system to recognize and attack cancer cells. This antibody has shown promising results in preclinical studies and is currently being evaluated in clinical trials as a potential therapeutic option for various types of cancer.

Structure of Balstilimab Biosimilar

Balstilimab biosimilar is a monoclonal antibody, meaning it is derived from a single type of immune cell and is highly specific in targeting a particular protein. It is a fully humanized antibody, meaning it is made entirely from human components and is less likely to cause an immune response in patients. The antibody is composed of two heavy chains and two light chains, each with a specific sequence of amino acids that determine its structure and function. The variable region of the antibody binds to the PD-1 protein, while the constant region interacts with other components of the immune system to initiate an immune response against cancer cells.

Mechanism of Action

The PD-1 protein is primarily expressed on the surface of T cells, a type of immune cell responsible for recognizing and destroying abnormal cells in the body. When PD-1 binds to its ligands, PD-L1 and PD-L2, it sends a signal to the T cells to become inactive and stop attacking. This mechanism is essential for maintaining immune homeostasis and preventing autoimmunity. However, cancer cells can also express PD-L1 and PD-L2, which allows them to evade the immune system and continue to grow and spread. Balstilimab biosimilar works by binding to the PD-1 protein, preventing it from interacting with its ligands and restoring the activity of T cells. This enables the immune system to recognize and eliminate cancer cells.

Clinical Applications

Balstilimab biosimilar is currently being evaluated in clinical trials for the treatment of various types of cancer, including melanoma, non-small cell lung cancer, and head and neck cancer. In a phase 1/2 clinical trial, balstilimab biosimilar showed promising results in patients with advanced solid tumors, with an overall response rate of 32%. In another phase 2 clinical trial, it demonstrated significant antitumor activity in patients with advanced cervical cancer, with an overall response rate of 26%. These results suggest that balstilimab biosimilar has the potential to be an effective treatment option for a wide range of cancers.

Advantages of Balstilimab Biosimilar

Balstilimab biosimilar offers several advantages over other anti-PD-1 antibodies currently on the market. As a biosimilar, it is a more affordable alternative to the original anti-PD-1 antibody, making it more accessible to patients. It is also a fully humanized antibody, reducing the risk of an immune response and making it more suitable for long-term treatment. Additionally, balstilimab biosimilar has shown promising results in clinical trials, making it a potential option for patients who do not respond to other treatments.

Conclusion

Balstilimab biosimilar is a novel antibody targeting the PD-1 protein, which plays a critical role in regulating the immune response. By blocking PD-1, this antibody enables the immune system to recognize and attack cancer cells, making it a promising therapeutic option for various types of cancer. With its unique structure, mechanism of

Balstilimab Biosimilar - Anti-PDCD1, PD1, CD279 mAb binds to CD279 Recombinant Protein in indirect ELISA Assay

Immobilized CD279 Recombinant Protein (cat. No.PX-P4117) at 0.5µg/mL (100µL/well) can bind to Balstilimab Biosimilar - Anti-PDCD1, PD1, CD279 mAb (cat. No.PX-TA1558) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450